UPDATE: Eiry Roberts leaves Lilly to become Neurocrine CMO

8 January 2018

US biotech Neurocrine Biosciences (Nasdaq: NBIX) has named an experienced Eli Lilly (NYSE: LLY) executive its new chief medical officer after Christopher O'Brien announced that he would be retiring.

Dr O’Brien has led Neurocrine’s clinical development and medical affairs activities for more than 12 years, a period which has seen US approval granted for Ingrezza (valbenazine) in tardive dyskinesia and the clinical development programs advanced for Tourette syndrome, Parkinson's disease, endometriosis and congenital adrenal hyperplasia. He will remain an exclusive consultant for the San Diego-based company after his retirement next month.

His replacement is Eiry Roberts, whose 25 years of research and development experience in pharma has come across all phases of drug development from research through commercialization in multiple therapeutic areas, including neuroscience, inflammation, oncology and metabolic diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK